Nancy King to United States
This is a "connection" page, showing publications Nancy King has written about United States.
Connection Strength
0.603
-
King NM. Who's Winning the IRB Wars? The Struggle for the Soul of Human Research. Perspect Biol Med. 2018; 61(3):450-464.
Score: 0.087
-
Robeson R, King NM. Loss of possession: concussions, informed consent, and autonomy. J Law Med Ethics. 2014; 42(3):334-43.
Score: 0.066
-
Freedman BI, Fletcher AJ, Sanghani VR, Spainhour M, Graham AW, Russell GB, Cooke Bailey JN, Iltis AS, King NM. Perceptions regarding genetic testing in populations at risk for nephropathy. Am J Nephrol. 2013; 38(6):453-7.
Score: 0.065
-
King NM. Nanomedicine first-in-human research: challenges for informed consent. J Law Med Ethics. 2012; 40(4):823-30.
Score: 0.057
-
King NM, Iltis AS. Introduction: research ethics: reexamining key concerns. J Law Med Ethics. 2012; 40(4):865-6.
Score: 0.057
-
Walker RL, King NM. Biodefense research and the U.S. regulatory structure whither nonhuman primate moral standing? Kennedy Inst Ethics J. 2011 Sep; 21(3):277-310.
Score: 0.056
-
King NM. The ethics of genetic testing: is more always better? N C Med J. 2007 Mar-Apr; 68(2):112-4.
Score: 0.041
-
King NM. The line between clinical innovation and human experimentation. Seton Hall Law Rev. 2003; 32(3):571-80.
Score: 0.031
-
King NM. RAC oversight of gene transfer research: a model worth extending? J Law Med Ethics. 2002; 30(3):381-9.
Score: 0.029
-
Friedmann T, Jonlin EC, King NMP, Torbett BE, Wivel NA, Kaneda Y, Sadelain M. ASGCT and JSGT Joint Position Statement on Human Genomic Editing. Mol Ther. 2015 Aug; 23(8):1282.
Score: 0.018
-
Macklin R, Shepherd L, Dreger A, Asch A, Baylis F, Brody H, Churchill LR, Coleman CH, Cowan E, Dolgin J, Downie J, Dresser R, Elliott C, Epright MC, Feder EK, Glantz LH, Grodin MA, Hoffman W, Hoffmaster B, Hunter D, Iltis AS, Kahn JD, King NM, Kraft R, Kukla R, Leavitt L, Lederer SE, Lemmens T, Lindemann H, Marshall MF, Merz JF, Miller FH, Mohrmann ME, Morreim H, Nass M, Nelson JL, Noble JH, Reis E, Reverby SM, Silvers A, Sousa AC, Spece RG, Strong C, Swazey JP, Turner L. The OHRP and SUPPORT--another view. N Engl J Med. 2013 Jul 11; 369(2):e3.
Score: 0.016
-
Fatehi L, Wolf SM, McCullough J, Hall R, Lawrenz F, Kahn JP, Jones C, Campbell SA, Dresser RS, Erdman AG, Haynes CL, Hoerr RA, Hogle LF, Keane MA, Khushf G, King NM, Kokkoli E, Marchant G, Maynard AD, Philbert M, Ramachandran G, Siegel RA, Wickline S. Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging field. J Law Med Ethics. 2012; 40(4):716-50.
Score: 0.014
-
King NM, Henderson G. Treatments of last resort: informed consent and the diffusion of new technology. Mercer Law Rev. 1991; 42(3):1007-50.
Score: 0.013
-
Hall MA, Friedman JY, King NM, Weinfurt KP, Schulman KA, Sugarman J. Commentary: Per capita payments in clinical trials: reasonable costs versus bounty hunting. Acad Med. 2010 Oct; 85(10):1554-6.
Score: 0.013
-
Weinfurt KP, Hall MA, King NM, Friedman JY, Schulman KA, Sugarman J. Disclosure of financial relationships to participants in clinical research. N Engl J Med. 2009 Aug 27; 361(9):916-21.
Score: 0.012
-
Kipnis K, King NM, Nelson RM. An open letter to institutional review boards considering Northfield Laboratories' PolyHeme trial. Am J Bioeth. 2006 May-Jun; 6(3):18-21.
Score: 0.010
-
Kipnis K, King NM, Nelson RM. Trials and errors: barriers to oversight of research conducted under the emergency research consent waiver. IRB. 2006 Mar-Apr; 28(2):16-9.
Score: 0.010
-
Henderson GE, Easter MM, Zimmer C, King NM, Davis AM, Rothschild BB, Churchill LR, Wilfond BS, Nelson DK. Therapeutic misconception in early phase gene transfer trials. Soc Sci Med. 2006 Jan; 62(1):239-53.
Score: 0.009